BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Theres a lot of confusion about the difference between BPC 157 arginate and acetate forms, so lets clear that up. The key distinction comes down to stability in the gut. This only applies to oral Is BPC 157 Banned? Oral vs. Injectable Forms Explained Comparing Rapid BPC 157 and Time Release for Gut Health